Abstract:The aim of this study was to elaborate the expression of HDAC4 in hepatocellular carcinoma and correlation with prognosis as well as clinical parameters. We chose a hepatocellular carcinoma tissue microarray with follow-up information (containing 90 hepatocellular carcinoma specimens). Immunohistochemistry was applied to investigate the expression level of HDAC4. The relationship between HDAC4 expression and the prognosis of early or later stage hepatocellular carcinoma were statistically analyzed by SPSS software respectively. HDAC4, expressed specifically in the cytoplasm, and also obviously higher in hepatocellular carcinoma tissues than para-carcinoma tissues (P<0.05). In the group of early hepatocellular carcinoma (stage1/stage2), the expression of HDAC4 was not correlated with ki67 expression (P=0.157); HDAC4 overexpression had better prognosis, although the p value was not significant (81.8% VS 48.3%, P=0.057). The expression of ki67 was not correlated with prognosis in this group (P=0.933). In the group of advanced hepatocellular carcinoma (stage3/stage4), the expression of HDAC4 was significantly correlated with ki67 expression (r=0.434, P=0.005); these two proteins were significantly negative correlation with prognosis in this group respectively (0% VS 27.3%, P=0.003; 0% VS 28.6%, P=0.000), COX multifactors analysis indicated that ki67 and M stage were independent predictors of this group (p=0.046, p=0.028). Conclusions: We hypothesized that HDAC4 might be regulated by different genes and perform different functions in different stages of hepatocellular carcinoma. In the early stage hepatocellular carcinoma patients, HDAC4 might participate an unknown tumor suppress network and prolong the survival time of patients; in the later stage of hepatocellular carcinoma, HDAC4 might be involved in the ki67 signaling network and indirectly promote the proliferation of hepatocellular carcinoma cells and reduced the survival time of patients. Because of the complexity of the biological function of HDAC4 in hepatocellular carcinoma, it might not all HCC patients can benefit from HDAC4 inhibitors in the treatment, it is necessary to do a further study on the clinical application of HDAC4 inhibitors.

Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma.

HDAC2 Regulates Cell Proliferation, Cell Cycle Progression and Cell Apoptosis in Esophageal Squamous Cell Carcinoma EC9706 Cells

Over-expression of HDAC8 Down-Regulate CDKN2A is Associated with Worse Prognosis of Esophageal Squamous Cell Carcinoma

Integrative Analysis of Histone Acetylation Regulated CYP4F12 in Esophageal Cancer Development

Expression of HDAC8 Indicates Poor Prognosis of Esophageal Squamous Cell Carcinoma and Progression to Advanced Stage

CDK4 Amplification in Esophageal Squamous Cell Carcinoma Associated with Better Patient Outcome

HDAC2 enhances esophageal squamous cell carcinoma development through down-regulating microRNA-503-5p and promoting CXCL10

RETRACTED: Over-expression of HDAC8 down-regulate CDKN2A is associated with worse prognosis of esophageal squamous cell carcinoma (Retracted Article)

High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy

Abnormally High HIP1 Expression is Associated with Metastatic Behaviors and Poor Prognosis in ESCC

Expression of HDAC 4 in hepatocellular carcinoma and its correlation with prognosis

Overexpression Of Chd1l Is Associated With Poor Survival And Aggressive Tumor Biology In Esophageal Carcinoma

Activation of histamine H4 receptor suppresses the proliferation and invasion of esophageal squamous cell carcinoma via both metabolism and non-metabolism signaling pathways

Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF1

Upregulation of OATP1A2 in Human Oesophageal Squamous Cell Carcinoma Cells Via the HDAC6-GCN5/PCAF-H3K9Ac Axis.

DNMT3A promotes the proliferation and metastasis of esophageal squamous cell carcinoma via upregulating HDAC9

Down-regulation of EphB4 phosphorylation is necessary for esophageal squamous cell carcinoma tumorigenecity

Over-expression of Oct4 in human esophageal squamous cell carcinoma

HDAC4 Promotes Nasopharyngeal Carcinoma Progression and Serves As a Therapeutic Target

Cytoplasmic HDPR1 is Involved in Regional Lymph Node Metastasis and Tumor Development Via Beta-Catenin Accumulation in Esophageal Squamous Cell Carcinoma

Retracted: Silence of HDAC6 Suppressed Esophageal Squamous Cell Carcinoma Proliferation and Migration by Disrupting Chaperone Function of HSP90